NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation for the quarter ended June 30, 202020-08-2020
NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation for the quarter ended June 30, 2020Earnings Call Transcript - Q1FY21 for Natco Pharma
Conference Call with Natco Pharma Management and Analysts on Q1FY21 Performance and Outlook. Listen to the full earnings transcript.Natco Pharma Q1 net down 14.5% at 122 cr
Natco Pharma Limited's consolidated net profit for the quarter ended June 30, 2020 slid by 14.5 per cent to 122.1 crore against 142.8 crore duringNATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Dividend Updates
Declaration of interim dividend of Rs.1.25 ps. per equity share of Rs.2/- each for the financial year 2020-21. The date for taking a record of its shareholders eligible for the purpose of payment of interim dividend i.e. Record date is fixed for 24th August, 2020. The said interim dividend pay-by-date is on or before 31st August, 2020NATCO PHARMA LTD. - 524816 - Record Date For Payment Of Interim Dividend
Record date for Payment of Interim DividendNATCO PHARMA LTD. - 524816 - Board declares Interim Dividend
Natco Pharma Ltd has informed BSE that the Board of Directors of the Company at its meeting held on August 12, 2020, inter alia, have considered and approved the following :- Declaration of interim dividend of Rs. 1.25 ps. per equity share of Rs. 2/- each for the financial year 2020-21. The said interim dividend pay-by-date is on or before August 31, 2020.NATCO PHARMA LTD. - 524816 - Outcome Of Board Meeting
Un audited financial results for the quarter ended june 30, 2020NATCO PHARMA LTD. - 524816 - Outcome Of Board Meeting
Un audited financial results for the quarter ended june 30, 2020NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Earning call for Q1 FY21NATCO PHARMA LTD. - 524816 - Board to consider Q1 results & Interim Dividend on August 12, 2020
Natco Pharma Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled to be held on August 12, 2020, inter alia, to consider the following items of businesses and related matters:1. To consider Un-audited Financial Results for the quarter ended June 30, 2020 (Q1).2. To consider interim dividend, if any for the financial year 2020-21.Further, pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015, TRADING WINDOW for dealing in the securities of the Company by the Employee(s) / Director(s) and their immediate relatives will be closed from August 04, 2020 to August 14, 2020 (both days inclusive). Trading window will be opened on August 17, 2020.